Ironwood Pharmaceuticals, Inc. · NASDAQ:IRWD
Ironwood Pharmaceuticals — Q2 2021 Earnings Presentation
16 slides from Ironwood Pharmaceuticals's earnings presentation, Aug 5, 2021
Slide 1: Ironwood 2Q 2021 Earnings Update
Ironwood 2Q 2021 Earnings Update August 5, 2021
Slide 2: Introduction
Introduction Matt Roache
Slide 3: Safe Harbor Statement
Safe Harbor Statement This presentation contains forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements, including statements about our ability to execute on our vision and mission; our strategy, business, financial position and operations
Slide 4: Today's Agenda
Today’s Agenda • Introduction Matt Roache, Director of Investor Relations • Q2 Overview, Strategic Priorities and Commercial Performance Tom McCourt, Chief Executive Officer • Q2 Financial Highlights & Updated 2021 Guidance Jason Rickard, Chief Operating Officer 4
Slide 5: Q2 Overview, Strategic Priorities and Commercial Performance
Q2 Overview, Strategic Priorities and Commercial Performance Tom McCourt
Slide 6: Our Strategy: Advancing Innovative Treatments for GI Diseases
We Aim to: Our Strategy: Maximize LINZESS® Advancing Innovative Treatments for GI 1 (linaclotide) ▪ Drive LINZESS growth in demand and net sales ▪ Enhance linaclotide clinical utility through robust Diseases lifecycle management opportunities We have a refreshed focus in areas of high unmet need whe
Slide 7: Strong LINZESS demand in 2Q 2021 further strengthened its position as the IBS-C/CIC market share leader
Strong LINZESS demand in 2Q 2021 further strengthened its position as the IBS-C/CIC market share leader in the U.S. LINZESS Total Rx Demand1 LINZESS NBRx Volume Growth2 160,000 15,000,000 +26%* +14% y/y 140,000 14,000,000 120,000 13,000,000 100,000 12,000,000 80,000 11,000,000 60,000 10,000,000 40,0
Slide 8: Key factors driving the continued robust demand for LINZESS
We believe these key factors are driving the continued robust demand for LINZESS Strong execution of Increase in online commercial strategy searches and clicks & positive patient for constipation- and physician related terms and experience with higher LINZESS LINZESS; broad website traffic1 payer ac
Slide 9: 2Q Financial Performance and Updated 2021 Financial Guidance
2Q Financial Performance and Updated 2021 Financial Guidance Jason Rickard
Slide 10: Another quarter of double-digit revenue growth and profitability
We delivered another quarter of double-digit revenue growth and profitability $104M $259M Total Ironwood Revenues U.S. LINZESS Net Sales1 18% Y/Y growth Primarily driven by $100M in U.S. LINZESS collaboration revenue Primarily driven by 14% Y/Y prescription demand growth and favorable inventory chan
Slide 11: We are focused on delivering shareholder value
We are focused on delivering shareholder value Seek to allocate capital to highest return opportunities Total Shareholder Maximize LINZESS Return Return of Capital Seek to drive net sales growth via Board of directors authorized a share commercial innovation and repurchase program of up to $150 mill
Slide 12: We are raising our 2021 financial guidance
We are raising our 2021 financial guidance as a result of the strong growth in U.S. LINZESS demand Ironwood now expects: New Guidance Prior Guidance LINZESS U.S. net sales 6 to 8% 3 to 5% growth Total Ironwood revenue $390 - $410 million $370 - $385 million Adjusted EBITDA1 >$210 million >$190 milli
Slide 13: Thank You
Thank You ~ q ronwoo
Slide 14: Q2 2021 Financial Summary
Q2 2021 Financial Summary Reconciliation of GAAP results to non-GAAP financial measures1 Three Months Ended Three Months Ended June 30, 2021 June 30, 2020 (000s, except per share amounts) (000s, except per share amounts) GAAP net income $ 391,303 $ 25,204 Adjustments: Mark-to-market adjustments on t
Slide 15: Q2 2021 Financial Summary
Q2 2021 Financial Summary Reconciliation of GAAP net income to adjusted EBITDA Three Months Ended Three Months Ended June 30, 2021 June 30, 2020 (000s) (000s) GAAP net income1 $ 391,303 $ 25,204 Adjustments: Mark-to-market adjustments on the derivatives related to 3,166 467 convertible notes, net Re
Slide 16: Q2 2021 Financial Summary
Q2 2021 Financial Summary LINZESS U.S. Brand Collaboration Commercial Profit & Collaboration Revenue1 Ironwood & AbbVie Total Net Profit Three Months Ended Three Months Ended Three Months Ended Three Months Ended June 30, 2021 June 30, 2020 June 30, 2021 June 30, 2020 (000s) (000s) (000s) (000s) $ 2
Ironwood Pharmaceuticals — Q2 2021 Earnings Presentation on 6ix